Tag Archives: Alzheimer’s

The Sharing Economy: Pharma Version

The Twenty-First Century ‘Sharing Economy’ has achieved a high profile and been sometimes rewarded with massive valuations over the past few years, with AirBnB and Uber epitomizing the model of sharing the costs and benefits associated with an asset. The … Continue reading

Posted in Big Pharma, Biotech | Tagged , , , , , | Leave a comment

mAbMEN: It’s Not Over

Eli Lilly: Experimental Alzheimer’s drug shows some benefit  (AP) Eli Lilly’s Solanezumab Is the Alzheimer’s Drug Equivalent of the Internet Dress                (TheStreet) Lilly says drug slows Alzheimer’s in patients with mild disease (Reuters) Lilly’s Alzheimer’s Drug May Slow Patients’ Decline … Continue reading

Posted in Big Pharma, BioFollies, Biotech, Science | Tagged , , , , | Leave a comment

Aducanumab: Less Than Meets The Eye

The beta-amyloid target in Alzheimer’s has become, to put it politely, somewhat tarnished over the past several years. AN-1792, bapineuzumab, solanezumab, gantenerumab, plus several BACE and gamma-secretase inhibitors/modulators, have combined to form a conga-line of clinical disappointments, undulating its way … Continue reading

Posted in BioFollies, Biotech, Muddled Media, Science | Tagged , , | Leave a comment

A Momentary Lapse of Reason*

*Floyd, P.  1987 Every now and then, pharma/biotech companies do things that suggest that they had experienced a transient ischemic attack against their better judgment. Today there were two such events in the news: 1) Biogen-Idec and BIIB037 Biogen-Idec is … Continue reading

Posted in BioFollies, Biotech, Muddled Media | Tagged , , , | Leave a comment

Concepts for Consideration

 (from NeuroPerspective July-August 2014) 1) Biometheus and the Placebo Response Gene: Biometheus has licensed IP related to a COMT gene polymorphism that they believe identifies patients prone to placebo-response.  As they discussed in BioCentury, the developers have published work showing … Continue reading

Posted in Big Pharma, BioFollies, Biotech | Tagged , , , , , , , | 1 Comment

Prana’s AD Gamble Falls Short

Prana just reported that PBT2 did not produce benefit vis-a-vis AB plaque load, cognition, or metabolic function in their latest Phase II trial in prodromal/mild Alzheimer’s. A nonsignificant trend towards slowed hippocampal atrophy (2.6% vs. 4.2%) over twelve months was … Continue reading

Posted in BioFollies, Biotech | Tagged , , | Leave a comment

AstraZeneca: Good News, Bad News (revised)

(Correction in paragraph 3, regarding Targacept): The press coverage today was all about AZ’s decision to advance their BACEi for Alzheimer’s, AZD3293, into a Phase II/III trial that, if highly successful, could in theory serve as a single trial for … Continue reading

Posted in Big Pharma | Tagged , , , | Leave a comment